MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/87551225261436716

Медицинская библиотека · The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026

Nirmatrelvir-Ritonavir Versus Short-Course Remdesivir for Mild COVID-19 in High-Risk Hospitalized Patients: A Propensity Score-Matched Study.

Steuber Taylor D, Belk Madeline, Thayer Blain, Edwards Jonathan

СтатьяПеревод пока не подготовлен

Аннотация

Background

As coronavirus disease 2019 (COVID-19) has evolved, patients increasingly present with milder disease, raising questions about optimal management of those hospitalized for other conditions, but found to have COVID-19 with high risk of progression. While these patients may traditionally be managed with a 3-day course of remdesivir (RDV) and nirmatrelvir/ritonavir (N/R) in the outpatient setting, these therapies have not been explicitly studied in a similar population, but in the inpatient setting.

Objective

To evaluate outcomes with 3-day RDV versus 5-day N/R in high-risk hospitalized patients with mild COVID-19.

Methods

This single-center, retrospective, propensity score-matched cohort study included hospitalized adult patients who were found to have mild COVID-19 between January 2023 and December 2023. Patients were grouped by treatment received, including 3-day RDV or 5-day N/R. Baseline characteristics and risk factors for disease progression were collected. Endpoints included incidence of disease progression, need for oxygen and respiratory support, length of stay, 30-day readmission, and mortality.

Results

One-hundred and fifty patients were included in the analysis, with 75 in each group. Baseline characteristics between groups were similar. There was no significant difference in the rate of disease progression between the RDV and N/R group (19% vs 11%, respectively; P = 0.166). There was no difference in additional endpoints including hospital length of stay, 30-day readmission, or mortality.

Conclusion

There was no significant difference in rates of disease progression or other outcomes among high-risk hospitalized adults with mild COVID-19 treated with RDV or N/R. Larger studies are needed to confirm these findings.

Для цитирования: Steuber Taylor D, Belk Madeline, Thayer Blain, Edwards Jonathan. Nirmatrelvir-Ritonavir Versus Short-Course Remdesivir for Mild COVID-19 in High-Risk Hospitalized Patients: A Propensity Score-Matched Study.. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. 2026. DOI: 10.1177/87551225261436716.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.